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Abstract
Not only has accidental injury been shown to account for a significant health burden on all populations, regardless
of age, sex and geographic region, but patients with accidental injury frequently present with the psychiatric
condition of posttraumatic stress disorder (PTSD). Prevention of accident-related PTSD thus represents a potentially
important goal. Physicians in the field of psychosomatic medicine and critical care medicine have the opportunity
to see injured patients in the immediate aftermath of an accident. This article first briefly reviews the prevalence
and associated factors of accident-related PTSD, then focuses on a conceptual model of fear memory and
proposes a new, rationally hypothesized translational preventive intervention for PTSD through promoting
hippocampal neurogenesis by omega-3 fatty acid supplementation. The results of an open-label pilot trial of
injured patients admitted to the intensive care unit suggest that omega-3 fatty acid supplementation immediately
after accidental injury can reduce subsequent PTSD symptoms.
Introduction
Posttraumatic stress disorder (PTSD) is a serious pub-
lic health problem. Approximately 6.8% of persons in
the United States develop PTSD at some time in their
lives [1]. PTSD most often develops from traumatic
events such as rape, assault and combat, and results
far less frequently from experiencing natural disasters
and accidents [2]. However, accidental injury is a fre-
quent event and represents a considerable public
health burden worldwide. According to the Global
Burden of Disease Study, the top three contributors to
worldwide burden of disease in the year 2020 are
expected to be ischemic heart disease, major depres-
sion and motor vehicle accidents (MVAs) [3]. From
the Japanese perspective, in 2008 approximately one
million individuals were severely injured in MVAs, and
recent advances in critical care medicine have
increased the number of seriously injured patients who
are able to survive their injuries [4]. Over the past dec-
ade, increasing attention has been devoted to psychia-
tric morbidity after accidental injury [5-12] as well as
other critical illness requiring treatment in the inten-
sive care unit (ICU) [13]. Indeed, important roles for
mental health professionals in general hospitals are the
early identification of injured patients who are at risk
for developing PTSD and the prevention of the disorder.
It is difficult to eliminate traumatic antecedents alto-
gether, but preventive intervention for PTSD does seem
possible. Secondary prevention involves intervening in
the aftermath of a traumatic event to forestall the devel-
opment of PTSD [14]. At the present time, the most
well-known and evidence-based secondary preventive
intervention for PTSD is cognitive behavioral therapy
(CBT). A study by Roberts and colleagues [15] found
that trauma-focused CBT within 3 months of a trau-
matic event appeared to be effective for individuals with
traumatic stress symptoms, especially those who met the
threshold for a clinical diagnosis. Furthermore, a bro-
chure on bereavement designed as a proactive end-of-
life communication strategy was reported to decrease
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depression among relatives of patients dying in the ICU
[16]. Preliminary studies suggest that propranolol
[17,18] or cortisol [19,20] can reduce subsequent PTSD,
but controlled trials of pharmacologic prevention of
PTSD are scarce to date. Although trauma-focused CBT
has been demonstrated to be effective, there are few
practitioners of psychosomatic medicine working in cri-
tical care medicine, and more convenient and evidence-
based preventive intervention is desired.
This article provides an overview of the literature on
psychiatric morbidity in injured adults admitted to the
I C U ,w i t hs p e c i a le m p h a s i sp l a c e do nP T S Di no r d e rt o
understand the current situation in the field. Following
a discussion of the neurobiological mechanism of fear
memory, a novel, translational early intervention for
preventing PTSD is proposed in which fear memory is
minimized through the activation of hippocampal neu-
rogenesis [21].
Prevalence of PTSD after accidental injury
Recent studies with strict methodology have shown that
accident-related PTSD is fairly common (Figure 1). The
prevalence of PTSD determined by structured clinical
interviews with injured patients consecutively admitted
to the ICU or emergency department ranges from 5-
30% at 0-3 months after accidental injury [7,9,10,
12,22-24] to 2-23% at 4-12 months after [7,9-11,22-25].
Recent large epidemiological studies have reported a
17-23% point prevalence of questionnaire-estimated
clinically significant PTSD symptoms at 4-12 months
after accidental injury [5,6]. Comorbidity between PTSD
and major depression is also highly prevalent in these
injured patients [7,12,26].
It has been pointed out that traumatic brain injury,
subsequent traumatization, use of narcotic analgesia,
timing of assessment, sample selection, and the role of
litigation all have the potential to confound the results
for the prevalence of accident-related PTSD [27]. In
addition, Schnyder and colleagues found that intercul-
tural differences play an important role in the develop-
ment of PTSD [11]. Recently, the author and colleagues
examined the relation between infant mortality rate
and prevalence of PTSD in the reliable cross-country
data available [25]. Infant mortality rate is well known
to be associated with levels of basic health care, well-
developed technology, and medical advances and is also
commonly included as part of standard of living evalua-
tions in economics. We showed that infant mortality
rate was associated with the prevalence of PTSD and as
such, our study findings could provide a plausible expla-
nation for the observed discrepancies seen in the preva-
lence of PTSD following injury [25].
Risk factors for accident-related PTSD
Numerous studies have assessed the predictors of acci-
dent-related PTSD. Potential risk factors identified in
the early aftermath of the accident include increased
acute stress symptoms [28,29], female sex [28,29],
pre-injury depression [6], ICU admission following the
trauma [6], benzodiazepine prescription [6], intentional
injury [6], penetrating trauma [28], perceived threat to
life [12,26,28], increased heart rate at the time of
admission [7,12,30,31], elevated respiration rate on the
initial day of injury [30] and intrusive symptoms
[10,12]. On the contrary, ther i s ko fs u b s e q u e n tP T S D
might be reduced by the use of morphine during
trauma care, as demonstrated among US military per-
sonnel who experienced combat [32] and individuals
injured in accidents [33].
Consolidation of fear memory
The preclinical approaches to PTSD are examining the
mechanisms of memory consolidation and how this con-
solidation process could be interrupted to prevent the
development of trauma-related disorders. An excellent
review by Ressler and Mayberg [34] notes that preclinical
studies have demonstrated that memories do not imme-
diately become permanent at the time of initial experi-
ence. They exist in a labile state for at least a period of
hours and possibly days, during which time they become
consolidated into more permanent memory. During this
consolidation, molecular, synaptic, neurotransmitter and
system-level changes occur consecutively [35]. The
neural circuitry implicated in fear memory likely involves
complex interactions between the hippocampus (which is
involved in short-term memory and probably fear of the
context of an event), the amygdala (which is involved in
conditioned fear response) and the medial prefrontal cor-
tex (which is believed to extinguish the more primitive
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Figure 1 Prevalence of posttraumatic stress disorder after
accidental injury. Acute and follow-up indicate 0-3 months and 4-
12 months after accidental injury, respectively. UK, United Kingdom;
ISR, Israel; USA, United States of America; CH, Switzerland; AUS,
Australia; JPN, Japan.
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PTSD also implicates the involvement of the amygdala,
medial prefrontal cortex and hippocampus [37]. As the
hippocampus can process and temporarily store new
memory before transferring labile memory to the cortex
for permanent storage [38], it has been suggested that
during the immediate period after fear training in an ani-
mal model and after a traumatic event in human patients,
i tm a yb ep o s s i b l et om o d u l a t et h ec o n s o l i d a t i o no fn e w
fear memories in the process of being formed [14].
Role of hippocampal neurogenesis in memory
consolidation
In rodents, primates and humans, the dentate gyrus in
the hippocampus is one of the two brain regions with
lifelong neurogenesis. Despite the wealth of accumulat-
ing data on the characteristics of neurons in newborns,
the specific contribution of their generation to memory
formation by the hippocampus remains unclear [39].
Recently, Kitamura and colleagues showed that severe
impairment of hippocampal neurogenesis attenuated the
loss of hippocampus-dependent remote contextual fear
memory in mice, while conversely, exercise on a run-
ning wheel, which promotes neurogenesis, increased the
rate of loss of hippocampus-dependent contextual fear
memory [21]. The hippocampus-dependent periods for
fear memory are modulated by various conditions. Inde-
pendent lines of evidence strongly suggest that the level
of hippocampal neurogenesis plays a role in determining
the hippocampus-dependent period of memory in adult
rodents. In short, the level of hippocampal neurogenesis
was able to be modulated and was associated with a
causal relationship between adult neurogenesis and the
hippocampus-dependent period of fear memory. There-
fore, it is theoretically possible that promoting adult
neurogenesis early in the transition period might facili-
tate the clearance of fear memory from the hippocam-
pus (Figure 2).
Learningfear
(trauma)
Learningfear
(trauma)
Preexistingsensitivity Preexistingsensitivity
Hippocampus Neocortex
gy
(geneandenvironment)
gy
(geneandenvironment)
Memory
consolidation
Clearanceof
Remotememory Maintenance
memoryfromthe
hippocampus Promotingneurogenesis
OmegaͲ3fattyacids MinimizingPTSD
symptoms symptoms
Figure 2 Schematic illustration of the development of posttraumatic stress disorder (PTSD) focusing on modulating the consolidation
of fear memory through neurogenesis by omega-3 fatty acid supplementation. The strength and regulation of fear memory is affected by
many factors both before and after the fearful and traumatic event occurs. Genetic and environmental factors as well as brain function and
structure are associated with the risk of such an experience. Acquired memories undergo a period of consolidation, in which they shift from a
labile state to a more permanent state. Memories are initially dependent on the hippocampus, but hippocampal dependency progressively
decays over time, a process that is associated with a gradual increase in dependency on an extra-hippocampal region such as neocortex (solid
arrows and box). We propose that promoting adult neurogenesis by omega-3 fatty acid supplementation early in the transition period might
facilitate clearance of fear memory from the hippocampus and consequently minimize PTSD symptoms (dotted arrows and box).
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According to Pitman’s theory of the pathogenesis of PTSD
[40], in trauma victims who develop the disorder, the trau-
matic event stimulates an excess release of stress hor-
mones, which in turn over-consolidates fear memories of
the event, which subsequently manifest themselves in the
intrusive recollections and re-experiencing symptoms
characteristic of PTSD. Fear consolidation can be blocked
after training by an antagonist of noradrenergic activation.
Such an antagonist is propranolol, a common beta-blocker
used for hypertension, and following on from animal
research, its effectiveness for the secondary prevention of
PTSD has been studied in clinical trials [17,18]. However,
as traumatized people are not psychiatric patients, daily
life-based intervention for prevention of PTSD is prefer-
able. From my own clinical experience, prophylactic phar-
macotherapy targeting subsequent psychiatric illness for
injured patients would not be allowed easily.
As much as diet has an impact on cardiovascular health,
cancer risk and longevity, it also has an impact on mental
health [41]. Adult hippocampal neurogenesis has been
directly linked to cognition and mood [42]; therefore,
modulating adult hippocampal neurogenesis by diet could
emerge as a possible mechanism by which nutrition
impacts on mental health. Taken together with Pitman’s
theory and the conceptual model of fear memory pre-
sented herein, it is possible that PTSD can be prevented
by facilitating hippocampal neurogenesis in the aftermath
of a traumatic event to modulate memory consolidation.
Omega-3 fatty acids and hippocampal
neurogenesis
A growing number of epidemiological studies have sug-
gested an association between mental health and
reduced dietary intake of omega-3 fatty acids, essential
fatty acids that humans cannot synthesize de novo.
Recent clinical trials are supportive of omega-3 fatty
acid supplementation in reducing depressive symptoms,
although it reduces anxiety symptoms only slightly
[43,44]. Based on the animal research to date, omega-3
fatty acids are the most promising candidate for dietary
intervention in the aftermath of a traumatic event to
facilitate adult hippocampal neurogenesis. Animal stu-
dies have revealed that short-term augmentation of diet-
ary omega-3 fatty acids relative to omega-6 fatty acids
up-regulated adult neurogenesis [45], and that dietary
omega-3 fatty acids elevated levels of brain-derived neu-
rotrophic factor (BDNF) which promotes neuronal sur-
vival and growth [46,47]. Further, docosahexaenoic acid
(DHA, 22:6n-3), a 22-carboned omega-3 fatty acid, pro-
moted the development of hippocampal neurons in vitro
by increasing neurite extension and branching [48] as
well as the maturation of neurons and hippocampal
neurogenesis in adult rats [49]. Venna and colleagues
have shown that the increase in newborn hippocampal
cells by polyunsaturated fatty acids occurred in parallel
with an increase in hippocampal volume and over-
expression of BDNF mRNA and protein in the hippo-
campus [50]. BDNF influences the survival of existing
neurons and the growth and differentiation of new neu-
rons, and is also implied in the regulation of various
neurotransmitter systems [51,52]. Moreover, BDNF
infused directly into the dorsal hippocampus of rats sig-
nificantly increased the granule cell layer, indicating
neurogenesis [53]. Wu and Gomez-Pinilla have indicated
that DHA dietary supplementation enhanced the effects
of exercise on cognition and BDNF-related synaptic
plasticity [47]. Evidence has accumulated that omega-3
fatty acids have an influence on hippocampal neurogen-
esis by increasing BDNF. In addition, Watanabe and
colleagues have revealed that brain fatty acid binding-
protein 7 (Fabp7) which preferentially binds DHA, plays
a significant role in neurogenesis, most likely thorough
maintenance of neural stem/progenitor cells [54].
The possible effects of omega-3 fatty acids on brain
structures are also highlighted by clinical observation. A
significant correlation was found between omega-3 fatty
acid consumption and gray matter volume of the amyg-
dala, hippocampus and anterior cingulate gyrus in
healthy adults [55]. Conversely, a selective deficit of
DHA was reported in the postmortem frontal cortex of
patients with depressive disorder [56]. Hippocampal
volume appears to be diminished in PTSD in some
[57-70] but not all studies [71-77]. The author and col-
leagues have reported smaller volumes of the amygdala
and hippocampus in a cohort of breast cancer survivors
experiencing intrusive recollections of traumatic mem-
ory, compared to survivors without intrusive recollec-
tions [78,79]. Furthermore, a significant negative
correlation has been shown between script-driven
enhanced emotional memory about MVA and urgent
surgery and hippocampal volume in healthy women
[80]. Two studies have suggested that hippocampal
volume might increase following treatment with antide-
pressants [81,82]. While the origin of small hippocampal
volume is unknown, the result of one twin study sug-
gested that small hippocampal volume might be a famil-
ial risk factor for developing PTSD [60]. As well, the
nutritional environment, including omega-3 fatty acids,
may contribute to hippocampal volume.
Clinical trial for PTSD prevention by omega-3
fatty acids
Support for the ability of omega-3 fatty acids to mini-
mize subsequent PTSD symptoms comes from one pub-
lished but preliminary open trial [83]. The author and
colleagues [83] recruited 15 consecutive patients
admitted to the ICU at a Japanese general hospital
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Patients received omega-3 fatty acid capsules containing
1,470 mg DHA and 147 mg eicosapentaenoic acid,
equivalent to 140 g of grilled cololabis saira ‘SANMA in
Japanese’, daily for 12 weeks. The primary efficacy vari-
able was score on the Clinician-Administered PTSD
Scale (CAPS). Omega-3 fatty acid supplementation was
well tolerated and resulted in a significantly increased
DHA concentration in erythrocytes. Compared with the
hypothetical mean in our previous cohort study [84],
omega-3 fatty acid supplementation resulted in a signifi-
cantly reduced mean CAPS total score (11 vs. 25, p =
0.03), and over the 12-week period, only one patient (1/
15, 6.7%) developed symptoms consistent with a diagno-
sis of both PTSD and major depression. Regarding the
adherence, significant differences in erythrocyte DHA
concentrations were confirmed between weeks 0 and 12
(mean % total fatty acids: 5.9 ± 1.4 vs. 8.4 ± 1.7, p <
.001). The author and colleagues also investigated the
potential role of BDNF as an underlying mechanism of
omega-3 fatty acid action for the prevention of PTSD
[85]. Serum BDNF was significantly elevated from weeks
0 to 12 (n = 11, 52.4 ± 16.7 vs. 79.8 ± 13.8, p = 0.001),
although it was largely unchanged in the two patients
who developed PTSD or major depression during the
trial. Change in the serum BDNF between weeks 0 to 12
was significantly larger in the non-distress group than in
the distress group, who met the criteria for PTSD or
major depression (median, 33.5; range, 8.5-56.0 vs. med-
ian, 5.4; range, 4.4-6.4, p = 0.037). Recently, Peters and
colleagues [86] have reported excellent work that BDNF
infused into the infralimbic medial prefrontal cortex (IL
mPFC) reduced conditioned fear, even in the absence of
extinction training. And they reported that rats failing to
learn extinction showed reduced BDNF in hippocampal
inputs to the IL mPFC and that augmenting BDNF in
this pathway prevented extinction failure. Hence, our
observation would be reasonable. Increasing BDNF activ-
ity in hippocampal BDNF may prove to be efficacious
intervention for PTSD. Because of the open-label design
and the lack of controls, however, no definitive conclu-
sion could be drawn from the trial and we must wait for
the results of an adequately powered randomized con-
trolled trial (ClinicalTrials.gov Identifier: NCT00671099)
(Figure 3). However, this pilot study has provided pro-
mising support for our hypothesis that omega-3 fatty
acid supplementation started shortly after accidental
injury may be efficacious in attenuating PTSD symptoms.
Conclusion and perspectives
This review has highlighted the major epidemiologic find-
ings of PTSD and possible nutritional intervention that
could be implemented in the aftermath of accidental
injury for prevention or amelioration of the disorder. It is
now becoming clearer that the modulation of adult hippo-
campal neurogenesis by diet affects learning, memory,
cognition and mood [41]. It is suggested that adult hippo-
campal neurogenesis may play a role in the periodic clear-
ance of hippocampal memory traces in contextual fear
conditioning [21]. Accordingly, adult hippocampal neuro-
genesis is emerging as a possible mediator of the effect of
diet on learning, memory, cognition and mood. Conse-
quently modulating adult hippocampal neurogenesis by
omega-3 fatty acid supplementation could be a target of
choice to prevent PTSD. Such intervention would likely be
acceptable in clinical practice in both mental health and
critical care medicine because of its convenience, empirical
results in animal studies and less frequent side effects. The
paucity of empirical data on nutritional intervention in the
immediate aftermath of extreme psychological trauma at
present indicates that more controlled trials based on
translational research are needed.
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